223 related articles for article (PubMed ID: 32932224)
1. The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.
Mastboom MJL; Lips W; van Langevelde K; Mifsud M; Ng C; McCarthy CL; Athanasou NA; Gibbons CLMH; van de Sande MAJ
Surg Oncol; 2020 Dec; 35():261-267. PubMed ID: 32932224
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.
Verspoor FGM; Mastboom MJL; Hannink G; Maki RG; Wagner A; Bompas E; Desai J; Italiano A; Seddon BM; van der Graaf WTA; Blay JY; Brahmi M; Eberst L; Stacchiotti S; Mir O; van de Sande MAJ; Gelderblom H; Cassier PA
Sci Rep; 2019 Oct; 9(1):14551. PubMed ID: 31601938
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
[TBL] [Abstract][Full Text] [Related]
4. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.
Mastboom MJL; Palmerini E; Verspoor FGM; Rueten-Budde AJ; Stacchiotti S; Staals EL; Schaap GR; Jutte PC; Aston W; Gelderblom H; Leithner A; Dammerer D; Takeuchi A; Thio Q; Niu X; Wunder JS; ; van de Sande MAJ
Lancet Oncol; 2019 Jun; 20(6):877-886. PubMed ID: 31029509
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; van der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY
Cancer; 2012 Mar; 118(6):1649-55. PubMed ID: 21823110
[TBL] [Abstract][Full Text] [Related]
6. Severity classification of Tenosynovial Giant Cell Tumours on MR imaging.
Mastboom MJL; Verspoor FGM; Hanff DF; Gademan MGJ; Dijkstra PDS; Schreuder HWB; Bloem JL; van der Wal RJP; van de Sande MAJ
Surg Oncol; 2018 Sep; 27(3):544-550. PubMed ID: 30217317
[TBL] [Abstract][Full Text] [Related]
7. Tenosynovial Giant Cell Tumors in Children: A Similar Entity Compared With Adults.
Mastboom MJL; Verspoor FGM; Uittenbogaard D; Schaap GR; Jutte PC; Schreuder HWB; van de Sande MAJ
Clin Orthop Relat Res; 2018 Sep; 476(9):1803-1812. PubMed ID: 29494352
[TBL] [Abstract][Full Text] [Related]
8. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.
Takeuchi A; Nomura A; Yamamoto N; Hayashi K; Igarashi K; Tandai S; Kawai A; Matsumine A; Miwa S; Nishida Y; Nakamura T; Terauchi R; Hoshi M; Kunisada T; Endo M; Yoshimura K; Murayama T; Tsuchiya H
BMC Musculoskelet Disord; 2019 Feb; 20(1):68. PubMed ID: 30738433
[TBL] [Abstract][Full Text] [Related]
9. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
[TBL] [Abstract][Full Text] [Related]
11. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
12. Management of tenosynovial giant cell tumour of the foot and ankle.
Spierenburg G; Lancaster ST; van der Heijden L; Mastboom MJL; Gelderblom H; Pratap S; van de Sande MAJ; Gibbons CLMH
Bone Joint J; 2021 Apr; 103-B(4):788-794. PubMed ID: 33789469
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.
Spierenburg G; Grimison P; Chevreau C; Stacchiotti S; Piperno-Neumann S; Le Cesne A; Ferraresi V; Italiano A; Duffaud F; Penel N; Metzger S; Chabaud S; van der Heijden L; Pérol D; van de Sande MAJ; Blay JY; Gelderblom H
Eur J Cancer; 2022 Sep; 173():219-228. PubMed ID: 35932628
[TBL] [Abstract][Full Text] [Related]
14. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
[No Abstract] [Full Text] [Related]
15. Imaging features for diffuse-type tenosynovial giant cell tumor of the temporomandibular joint: A case report.
Hu Y; Kuang B; Chen Y; Shu J
Medicine (Baltimore); 2017 Jun; 96(26):e7383. PubMed ID: 28658169
[TBL] [Abstract][Full Text] [Related]
16. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.
Bernthal NM; Spierenburg G; Healey JH; Palmerini E; Bauer S; ; Gelderblom H; Staals EL; Lopez-Bastida J; Fronk EM; Ye X; Laeis P; van de Sande MAJ
Orphanet J Rare Dis; 2021 Apr; 16(1):191. PubMed ID: 33926503
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of arthroscopic excision based on the distribution of the tenosynovial giant cell tumor around knee joint.
Yoo HJ; Nam HS; Park SB; Lee YS
Knee; 2023 Mar; 41():360-372. PubMed ID: 36848705
[TBL] [Abstract][Full Text] [Related]
18. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
19. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function.
Verspoor FGM; Mastboom MJL; Hannink G; van der Graaf WTA; van de Sande MAJ; Schreuder HWB
Bone Joint J; 2019 Mar; 101-B(3):272-280. PubMed ID: 30813787
[TBL] [Abstract][Full Text] [Related]
20. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD; Gelderblom H; Palmerini E; Desai J; Bauer S; Blay JY; Alcindor T; Ganjoo K; Martín-Broto J; Ryan CW; Thomas DM; Peterfy C; Healey JH; van de Sande M; Gelhorn HL; Shuster DE; Wang Q; Yver A; Hsu HH; Lin PS; Tong-Starksen S; Stacchiotti S; Wagner AJ;
Lancet; 2019 Aug; 394(10197):478-487. PubMed ID: 31229240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
